Yan Hou

4.8k total citations
62 papers, 1.8k citations indexed

About

Yan Hou is a scholar working on Molecular Biology, Cancer Research and Reproductive Medicine. According to data from OpenAlex, Yan Hou has authored 62 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 20 papers in Cancer Research and 13 papers in Reproductive Medicine. Recurrent topics in Yan Hou's work include Metabolomics and Mass Spectrometry Studies (19 papers), Ovarian cancer diagnosis and treatment (13 papers) and Cancer-related molecular mechanisms research (8 papers). Yan Hou is often cited by papers focused on Metabolomics and Mass Spectrometry Studies (19 papers), Ovarian cancer diagnosis and treatment (13 papers) and Cancer-related molecular mechanisms research (8 papers). Yan Hou collaborates with scholars based in China, United States and Macao. Yan Hou's co-authors include Kang Li, Kai Yang, Mingzhu Yin, Ge Lou, Haiyu Zhang, Chunyan Yang, Chaofu Ke, Hongyu Xie, Zhenzi Li and Bairong Xia and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Yan Hou

59 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yan Hou China 24 1.1k 749 218 201 194 62 1.8k
Aleksandra Gentry‐Maharaj United Kingdom 27 1.1k 1.0× 622 0.8× 550 2.5× 701 3.5× 128 0.7× 86 2.5k
Dominique Könsgen Germany 18 645 0.6× 312 0.4× 274 1.3× 299 1.5× 53 0.3× 33 1.2k
Samuel L. Volchenboum United States 22 869 0.8× 562 0.8× 354 1.6× 105 0.5× 119 0.6× 66 1.9k
Matt J. Barnett United States 26 889 0.8× 378 0.5× 533 2.4× 225 1.1× 85 0.4× 53 2.4k
Khalil Helou Sweden 27 1.2k 1.1× 514 0.7× 508 2.3× 119 0.6× 167 0.9× 114 2.2k
Denise Scholtens United States 35 1.2k 1.1× 598 0.8× 510 2.3× 92 0.5× 178 0.9× 137 3.2k
Yingying Li China 26 891 0.8× 424 0.6× 438 2.0× 111 0.6× 284 1.5× 179 2.8k
Suzhan Zhang China 27 893 0.8× 491 0.7× 658 3.0× 67 0.3× 170 0.9× 89 2.3k
Jiekai Yu China 21 789 0.7× 240 0.3× 255 1.2× 61 0.3× 133 0.7× 73 1.5k
Rashid Mir India 25 1.0k 0.9× 542 0.7× 338 1.6× 84 0.4× 213 1.1× 139 2.1k

Countries citing papers authored by Yan Hou

Since Specialization
Citations

This map shows the geographic impact of Yan Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Hou more than expected).

Fields of papers citing papers by Yan Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Hou. The network helps show where Yan Hou may publish in the future.

Co-authorship network of co-authors of Yan Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Hou. A scholar is included among the top collaborators of Yan Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Hou. Yan Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Luying, et al.. (2025). Unlocking new horizons in oncology: ivonescimab’s dual-target approach to anti-VEGF/PD-1(L1) therapy. Frontiers in Immunology. 16. 1599181–1599181. 1 indexed citations
2.
Zhang, Tao, Mu Wei, Cheng‐Gong Liao, et al.. (2024). Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy. Cancer Chemotherapy and Pharmacology. 95(1). 13–13.
3.
Wang, Wenxiang, et al.. (2023). Cancer metabolites: promising biomarkers for cancer liquid biopsy. Biomarker Research. 11(1). 66–66. 49 indexed citations
4.
Wang, Wenjie, Hongyu Xie, Bairong Xia, et al.. (2021). Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics. Journal of Cancer. 12(6). 1651–1659. 6 indexed citations
5.
Meng, Hua, et al.. (2020). The Relationship Between Human Papillomavirus, OFD1 and Primary Ciliogenesis in the Progression of Oropharyngeal Cancer: A Retrospective Cohort Study. SHILAP Revista de lepidopterología. 3 indexed citations
6.
Wu, Xiaoke, Kaijiang Yu, Yongchen Wang, et al.. (2020). The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol. Engineering. 6(10). 1199–1204. 14 indexed citations
7.
Zhou, Feng, et al.. (2020). Epidemiological Characteristics and Factors Associated with Critical Time Intervals of COVID-19 in Eighteen Provinces, China: A Retrospective Study. International Journal of Infectious Diseases. 102. 123–131. 3 indexed citations
8.
Yang, Chunyan, Ce Wang, Zhiwei Rong, et al.. (2020). <p>Mediation Analysis Reveals Potential Biological Mechanism of Ascites Influencing Recurrence in Patients with Epithelial Ovarian Cancer</p>. Cancer Management and Research. Volume 12. 793–799. 3 indexed citations
9.
Sun, Yuhong, Yan Hou, Nan Lv, et al.. (2019). Circulating lncRNA BC030099 Increases in Preeclampsia Patients. Molecular Therapy — Nucleic Acids. 14. 562–566. 19 indexed citations
10.
Xia, Bairong, Mei Lin, Wei Dong, et al.. (2018). Upregulation of miR‐874‐3p and miR‐874‐5p inhibits epithelial ovarian cancer malignancy via SIK2. Journal of Biochemical and Molecular Toxicology. 32(8). e22168–e22168. 43 indexed citations
11.
Zhang, Fan, Yuanyuan Zhang, Chaofu Ke, et al.. (2018). Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery. Metabolomics. 14(5). 65–65. 21 indexed citations
12.
Yang, Kai, Weiwei Zhao, Ge Lou, et al.. (2018). An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance. Frontiers in Immunology. 9. 757–757. 6 indexed citations
13.
Yang, Kai, Yan Hou, Ang Li, et al.. (2017). Identification of a six-lncRNA signature associated with recurrence of ovarian cancer. Scientific Reports. 7(1). 11481–11481. 53 indexed citations
14.
Zhang, Haiyu, Tingting Ge, Xiaoming Cui, et al.. (2014). Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling. Molecular BioSystems. 11(2). 516–521. 21 indexed citations
15.
Hou, Yan, Mingzhu Yin, Fengyu Sun, et al.. (2014). A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. Molecular BioSystems. 10(8). 2126–2133. 40 indexed citations
16.
Sun, Meng, Xueqin Gao, Dongwei Zhang, et al.. (2013). Identification of biomarkers for unstable angina by plasma metabolomic profiling. Molecular BioSystems. 9(12). 3059–3067. 32 indexed citations
17.
Yin, Mingzhu, Yan Hou, Tao Zhang, et al.. (2013). Evaluation of Chemotherapy Response with Serum Squamous Cell Carcinoma Antigen Level in Cervical Cancer Patients: A Prospective Cohort Study. PLoS ONE. 8(1). e54969–e54969. 16 indexed citations
18.
Niu, Yucun, Rennan Feng, Yan Hou, et al.. (2011). Histidine and arginine are associated with inflammation and oxidative stress in obese women. British Journal Of Nutrition. 108(1). 57–61. 97 indexed citations
19.
Yin, Mingzhu, Ye Xu, Ge Lou, et al.. (2010). LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. International Journal of Cancer. 129(3). 629–635. 37 indexed citations
20.
Hou, Yan, et al.. (2009). Excellent effect of three-dimensional culture condition on pancreatic islets. Diabetes Research and Clinical Practice. 86(1). 11–15. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aleksandra Gentry‐Maharaj Breakdown of academic impact, for papers by Dominique Könsgen Breakdown of academic impact, for papers by Samuel L. Volchenboum Breakdown of academic impact, for papers by Matt J. Barnett Breakdown of academic impact, for papers by Khalil Helou Breakdown of academic impact, for papers by Denise Scholtens Breakdown of academic impact, for papers by Yingying Li Breakdown of academic impact, for papers by Suzhan Zhang Breakdown of academic impact, for papers by Jiekai Yu Breakdown of academic impact, for papers by Rashid Mir
Rankless by CCL
2026